Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone, with an initial treatment target of hypertension. The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor designed to reduce aldosterone levels by inhibiting the CYP11B2 enzyme. Mineralys is developing lorundrostat for the treatment of uncontrolled and resistant hypertension, as well as related cardiorenal conditions including chronic kidney disease and obstructive sleep apnea. The company completed six late-stage clinical trials, including pivotal Phase 3 and Phase 2 studies, supporting the efficacy and safety profile of lorundrostat. In December 2025, Mineralys submitted a New Drug Application to the FDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The company licensed lorundrostat from Tanabe Pharma Corporation, which discovered the compound and conducted the initial Phase 1 clinical development. Mineralys Therapeutics was formed in 2019.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage mineralystx.com
Sector Healthcare IR page ir.mineralystx.com
Tags
cardiovascular disease, hypertension, chronic kidney disease, obstructive sleep apnea, aldosterone synthase inhibitors, cardiorenal metabolic syndrome, lorundrostat, MLS-101, Tanabe Pharma Corporation, Mitsubishi Tanabe Pharmaceutical Company
Press page ir.mineralystx.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 2.225B
Market cap (USD) $ 2.225B
P/E -5.87
PEG —
P/BV 4.42
P/S —
P/OCF -14.54
P/FCF -15.62
Dividend yield —
Turnover / mcap —
Returns  
ROE -36.9%
ROI -23.9%
ROIC -19.8%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 0.02%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 56
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 661.806M 205.903M 251.636M 114.442M 11.125M —
Net profit -154.651M -177.81M -71.898M -29.799M -19.408M 0
Free cash flow -142.431M -166.41M -81.173M -29.221M -14.559M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 36.29 12.31 8.6 — — —
Price performance 12m 1.95 0.43 — — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Cash and deposits (USD) 10.7M 87.7M 49.3M 114M 173M
Cash flow detail
Operating cash flow (USD) — -29.2M -81.2M -166M -142M
Purchases of property, plant and equipment (USD) — — 0.00 -96,000 -15,000
Change in payables (cash effect) (USD) — 3.01M 2.42M 4.16M 427,000
Share-based compensation (USD) — 455,000 5.06M 11.3M 19.3M
Free cash flow (OCF - PPE - intangibles) (USD) — — -81.2M -166M -142M
Income detail
Research and development expense (USD) — 26.3M 70.4M 169M 132M
Reported May 15, 2023 Mar 21, 2024 Feb 12, 2025 Feb 12, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 06, 2026 8:00 am EST Download as PDF

RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on November 3, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 14,880 shares and an inducement restricted stock unit award covering 11,160 shares of Mineralys common stock to a new non-executive employee.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option award will vest over a four-year period, with 25% of the total shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, November 2, 2026, and 1/48th of the total shares underlying the award vesting following each one-month period thereafter, subject to continued service. The restricted stock unit award will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the award’s vesting commencement date, November 2, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn , X and Bluesky .

November 04, 2026 4:05 pm EST Download as PDF

Related Documents

Earnings Webcast

Audio

10-Q Filing

HTML PDF

XBRL

ZIP

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 –

– New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hypertension receiving lorundrostat 50 mg achieved the AHA/ACC guideline systolic blood pressure target of <130 mmHg at Week 12 –

– Transform-HTN open-label extension trial data selected for late-breaking presentation at American Heart Association Scientific Sessions 2026 –

– Conference call today at 4:30 p.m. ET –

RADNOR, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval,” said Jon Congleton, Chief Executive Officer of Mineralys. “We also continue to highlight the data from our clinical trials in meetings with physicians and through presentations at scientific congresses, including our recent updates at AHA-HTN and ASN Kidney Week, and our upcoming presentation at the AHA Scientific Sessions. We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”

Recent Highlights and Upcoming Milestones

  • Lorundrostat New Drug Application (NDA) — The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.
  • New Launch-HTN and Explore-OSA Data at the American Heart Association Hypertension Scientific Sessions (AHA-HTN) and American Society of Nephrology (ASN) Kidney Week 2026
    • A new analysis of the pivotal Phase 3 Launch-HTN trial showed that at Week 12, 46% of lorundrostat-treated participants (50 mg) achieved the AHA/ACC guideline-recommended office systolic blood pressure (SBP) target of <130 mmHg, with more than two-thirds achieving an SBP reduction of ≥10 mmHg. Participants had uncontrolled or treatment-resistant hypertension despite treatment with two to five antihypertensive therapies.
    • An additional new analysis from Launch-HTN demonstrated that lorundrostat achieved similar blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD. Lorundrostat also reduced albuminuria by 52% versus placebo, validating similar findings in a prior trial in participants with established CKD.
    • Final results from the Phase 2 Explore-OSA trial in overweight or obese adults with moderate-to-severe OSA and hypertension showed that lorundrostat 50 mg taken once daily in the evening reduced morning SBP by 11.1 mmHg at Week 4 (p<0.0001), compared with a 1.0 mmHg reduction with placebo (p=NS). No measurable change in apnea-hypopnea index was observed. Lorundrostat exhibited a favorable safety and tolerability profile, with no evidence of serious safety events, including hyperkalemia.
  • Transform-HTN Open-Label Extension Trial — New long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial will be featured in a late-breaking presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.
  • Commercial Launch Readiness — The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place. The Company continues to engage with leading hypertension experts and payers. Brand marketing preparations are well underway, and the Company is finalizing a full-service patient support program designed to ease access for physicians, their office staff and patients.

Third Quarter 2026 Financial Highlights

Cash, cash equivalents and investments were $624.7 million as of September 30, 2026, compared to $656.6 million as of December 31, 2025. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028.

Research and development (R&D) expenses for the quarter ended September 30, 2026, were $22.7 million, compared to $31.5 million for the quarter ended September 30, 2025. The decrease in R&D expenses was primarily due to $8.5 million of lower preclinical and clinical costs resulting from the conclusion of the lorundrostat pivotal program in the second quarter of 2025 and $0.3 million of decreased clinical supply, manufacturing, regulatory and other costs.

General and administrative (G&A) expenses were $37.4 million for the quarter ended September 30, 2026, compared to $9.7 million for the quarter ended September 30, 2025. The increase in G&A expenses was primarily due to investments to expand the Company’s operations in preparation for commercialization, including $15.4 million in higher professional fees and $11.4 million in increased personnel-related expenses resulting from headcount growth and increased compensation, as well as $0.9 million of increased other administrative expenses.

Total other income, net was $2.8 million for the quarter ended September 30, 2026, compared to $4.2 million for the quarter ended September 30, 2025. The decrease was primarily due to $3.2 million of increased interest expense related to the senior secured term loan entered into in June 2026, partially offset by $1.8 million of increased interest earned on investments as a result of higher average cash balances during the quarter ended September 30, 2026.

Net loss was $57.3 million for the quarter ended September 30, 2026, compared to $36.9 million for the quarter ended September 30, 2025. The increase was primarily attributable to the factors impacting the Company’s expenses described above.

Conference Call

The Company’s management team will host a conference call at 4:30 p.m. ET today, November 4, 2026. To access the call, please dial 1-877-704-4453 in the United States or 1-201-389-0920 outside the United States, referencing conference ID 13762560. A live webcast of the conference call may be found here . A replay of the call will be available on the “News & Events” page in the Investors section of the Mineralys website here .

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn , X and Bluesky .

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding: the anticipated timing of the FDA’s review of Mineralys’ accepted NDA; the potential therapeutic benefits of lorundrostat; Mineralys’ expectations regarding activities to prepare for the commercial launch of lorundrostat; and the sufficiency of Mineralys’ cash, cash equivalents and investments to fund its operations. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the FDA’s review of Mineralys’ accepted NDA, including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Prompts

Mineralys Therapeutics, Inc. (ticker MLYS), listed in United States.

ETFs Holding Mineralys Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
ESSC 0.14% 2,032 $ 51.857K Jul 31, 2026
FSEG 0.14% 300 $ 8,094.00 Jun 30, 2026
RUSC 0.13% 3,808 $ 102.74K Jun 30, 2026
FFSM 0.07% 39,638 $ 1.012M Jul 31, 2026
RESM 0.06% 76 $ 2,050.48 Jun 30, 2026
FESM 0.02% 44,038 $ 1.188M Jun 30, 2026
DFAS 0.01% 239,025 $ 3.705M Nov 12, 2026
MSSM 0.01% 1,798 $ 46.155K Aug 31, 2026
DFAC 0.00% 105,708 $ 1.638M Nov 12, 2026
DCOR 0.00% 19,205 $ 297.678K Nov 12, 2026
DXUV 0.00% 1,718 $ 26.629K Nov 12, 2026
DFAU 0.00% 1,940 $ 30.07K Nov 12, 2026
DFUS 0.00% 1,838 $ 28.489K Nov 12, 2026
AVSC 0.00% 466 $ 6,770.98 Nov 16, 2026